Musings from The Power List: Ali Pashazadeh
By Ali Pashazadeh
August 7, 2026
Ali Pashazadeh argues that management failures sink too many clinical programs – and explains why commercial discipline must start much earlier
7 min read
False
Advertisement
Biopharma
Moving Glycosylation Control Upstream
August 6, 2026
Samsung Biologics’ Sojeong Lee discusses why biologics developers are paying closer attention to glycosylation earlier in development.
7 min read
How China Is Rewriting the Rules Global Drug Development
By James Strachan
August 5, 2026
In part two of our conversation, Lingshi Tan explores how China’s integrated biopharma ecosystem is reshaping assumptions about speed, cost, innovation, and cross-border clinical development
14 min read
The 10 Biggest Bottlenecks Slowing Drug Development
August 4, 2026
Ten industry leaders from the 2026 Power List identify the scientific, clinical, regulatory, and financial barriers holding drug development back
6 min read
Why Traditional Biomanufacturing Models are Faltering
By Andrea Johnston
July 29, 2026
As product pipelines become more varied, biomanufacturers are rethinking how facilities, data systems and workforce skills support day-to-day operations
6 min read
The New Rules of Global Drug Development
By James Strachan
July 28, 2026
Caidya Executive Chairman Lingshi Tan explains why capital discipline, early clinical execution, and global development strategy are becoming central to biotech success
8 min read
Biopharma Vital Signs – Part 6: Advice for Emerging Biotechs
July 24, 2026
Industry experts share practical advice for emerging biotech companies navigating development decisions, funding pressures, manufacturing strategy, partner selection, and the path toward commercial readiness
9 min read
The Power List 2026 is Live
July 21, 2026
We celebrate 60 inspiring individuals helping turn pharma’s boldest ideas into reality
2 min read
Biopharma Vital Signs – Part 5: Capabilities for a Changing Landscape
July 17, 2026
Experts discuss the capabilities companies need to make drug development faster, more flexible, and more resilient – from integrated development and manufacturing flexibility to digital tools, supply chain strategy, and sharper decision-mak...
13 min read
The Rise of China: From Science Cities to Global Ambition
By James Strachan, Kathryn Wighton
July 15, 2026
Daphne Smyth of Veristat on the rise of Chinese biopharma, regulatory realities, and what comes next
8 min read
